2011 Scrip 100: Nothing is certain except change
This article was originally published in Scrip
Concerns over the lack of innovation in the pharmaceutical industry have been rumbling for some time, but one recently reported fact provides new grist for this mill: for the first time ever there were no new drug targets reported at this year's American Chemical Society (ACS) meeting.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.